glp 1 and brain fog A schematic representation of the potential role of GLP-1 Frontiers | Mechanisms of action

Endocrinology 147 , 37273736

While this research is promising, more studies and clearer guidance on less-frequent dosing are still needed

These medication pathways make it increasingly difficult for employers to maintain visibility into GLP-1 use and related risk, progress, or safety for their employees

A single-pulse sequence was applied to acquire dynamic DMRS spectra from the mouse brain with the following parameters: 2 KHz bandwidth, 512 data points for the free induction decay (FID), 64 flip angle, 350 ms repetition time (TR) with 800 averages (5 min per spectrum) and a total of 15 spectra

Importantly, GLP-1RAs do not exert direct immunosuppressive effects but instead modulate inflammatory pathways indirectly through metabolic and cellular mechanisms, supporting a favourable safety profile when used alongside bDMARDs

Otherwise, the main difference is how you administer it